ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
TP53 Mutations in MDS: Is Combination of Eprenetapopt + AZA Well-Tolerated in Patients With TP53-Mutant MDS & Oligoblastic AML? What Are the Rates of Clinical Response & Molecular Remissions?
Comments 0
Login to view comments.
Click here to Login
